Scartozzi, Mario
 Distribuzione geografica
Continente #
NA - Nord America 1.694
AS - Asia 1.064
EU - Europa 531
SA - Sud America 280
AF - Africa 93
Totale 3.662
Nazione #
US - Stati Uniti d'America 1.636
SG - Singapore 366
CN - Cina 267
BR - Brasile 220
HK - Hong Kong 156
VN - Vietnam 142
IT - Italia 125
SE - Svezia 89
DE - Germania 63
GB - Regno Unito 58
CI - Costa d'Avorio 40
FR - Francia 39
CA - Canada 34
AR - Argentina 30
AT - Austria 29
RU - Federazione Russa 29
TR - Turchia 25
BG - Bulgaria 21
IN - India 19
NL - Olanda 19
BD - Bangladesh 18
FI - Finlandia 17
SN - Senegal 15
JP - Giappone 14
IQ - Iraq 13
ZA - Sudafrica 10
ES - Italia 9
MX - Messico 8
VE - Venezuela 8
EC - Ecuador 7
ID - Indonesia 7
UA - Ucraina 7
EG - Egitto 6
NG - Nigeria 6
PK - Pakistan 6
UZ - Uzbekistan 5
CZ - Repubblica Ceca 4
KE - Kenya 4
LT - Lituania 4
PA - Panama 4
AE - Emirati Arabi Uniti 3
AL - Albania 3
CL - Cile 3
CO - Colombia 3
CR - Costa Rica 3
MY - Malesia 3
PE - Perù 3
PH - Filippine 3
RO - Romania 3
SA - Arabia Saudita 3
UY - Uruguay 3
AO - Angola 2
BE - Belgio 2
BS - Bahamas 2
ET - Etiopia 2
IE - Irlanda 2
KZ - Kazakistan 2
MA - Marocco 2
NI - Nicaragua 2
NP - Nepal 2
PL - Polonia 2
PY - Paraguay 2
SI - Slovenia 2
SV - El Salvador 2
TN - Tunisia 2
BH - Bahrain 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CG - Congo 1
DO - Repubblica Dominicana 1
EE - Estonia 1
GD - Grenada 1
GH - Ghana 1
GT - Guatemala 1
IS - Islanda 1
JO - Giordania 1
KH - Cambogia 1
LB - Libano 1
LY - Libia 1
MK - Macedonia 1
MM - Myanmar 1
MU - Mauritius 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TJ - Tagikistan 1
TM - Turkmenistan 1
Totale 3.662
Città #
Ashburn 219
Singapore 212
Hong Kong 152
Santa Clara 150
San Jose 129
Chandler 102
Fairfield 81
Shanghai 80
Woodbridge 64
Dallas 58
Council Bluffs 48
New York 43
Abidjan 40
Houston 39
Wilmington 35
Boardman 34
Ho Chi Minh City 34
Los Angeles 32
Seattle 32
Beijing 31
Cambridge 31
Hanoi 29
Florence 28
Munich 24
Princeton 24
Vienna 24
Colorado Springs 23
Lawrence 21
Sofia 21
Lauterbourg 19
Milan 19
Istanbul 18
London 17
Medford 16
Dakar 15
Bremen 14
Ann Arbor 13
Ottawa 13
São Paulo 13
Buffalo 12
Frankfurt am Main 12
Tokyo 12
Haiphong 10
Kent 9
Montreal 9
Nuremberg 9
Redondo Beach 9
San Diego 9
Des Moines 8
Turku 8
Baltimore 7
Dearborn 7
Poplar 7
Baghdad 6
Chicago 6
Dong Ket 6
Fuzhou 6
Helsinki 6
Mexico City 6
Orem 6
Rio de Janeiro 6
Serra 6
Amsterdam 5
Bexley 5
Chennai 5
Guangzhou 5
Johannesburg 5
Lagos 5
Nanjing 5
Phoenix 5
Redwood City 5
Boston 4
Curitiba 4
Da Nang 4
Joinville 4
Lancaster 4
Miami 4
Murcia 4
New Delhi 4
Ogden 4
Panama City 4
Porto Alegre 4
Quanzhou 4
Quito 4
Seacroft 4
Stockholm 4
Thái Nguyên 4
Bitonto 3
Brasília 3
Brooklyn 3
Bảo Lộc 3
Bắc Ninh 3
Caracas 3
City of London 3
Denver 3
Elk Grove Village 3
Formosa 3
Fortaleza 3
Ha Long 3
Hebei 3
Totale 2.327
Nome #
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 181
Natural history of malignant bone disease in hepatocellular carcinoma: Final results of a multicenter bone metastasis survey 180
Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib. An INNOVATE Study Protocol 152
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 135
Association of NOS3 and ANGPT2 gene polymorphisms with survival in patients with hepatocellular carcinoma receiving sorafenib: Results of the multicenter prospective INNOVATE study 133
Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies 132
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: A fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis 131
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 128
Erratum to: Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy (The Oncologist, (2017), 22, 12, (1463-1469), 10.1634/theoncologist.2017-0158) 128
Corrigendum: Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? [Ann Oncol, 23, 9, (2012) (2313-2318)] doi: 10.1093/annonc/mdr623 125
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 120
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 118
Outcomes of advanced gastric cancer patients treated with at least three lines of systemic chemotherapy 118
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 117
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer 116
Cholangiocarcinoma: new perspectives for new horizons 115
A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy 113
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 112
Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index 110
Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations 109
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 108
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience 107
Selecting patients for gastrectomy in metastatic esophago-gastric cancer: Clinics and pathology are not enough 107
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer 104
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 103
Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients 89
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 67
Correction to: Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 61
Sequential Treatment of Sorafenib–Regorafenib Versus Sorafenib–Physician’s Choice: A Propensity Score-Matched Analysis 52
Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis 45
Viral Hepatitis in Western Patients with Advanced Intrahepatic Cholangiocarcinoma: Retrospective Assessment of Prevalence, Prognostic and Predictive Significance 40
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 39
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 38
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 37
Sequential Treatment of Sorafenib-Regorafenib Versus Sorafenib-Physician's Choice: A Propensity Score-Matched Analysis 36
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 33
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 32
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 32
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 32
Totale 3.735
Categoria #
all - tutte 12.155
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.155


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202120 0 0 0 0 0 0 0 0 0 0 3 17
2021/2022186 3 8 4 1 11 50 3 11 5 21 21 48
2022/2023396 38 60 32 24 40 45 6 24 88 2 31 6
2023/2024173 14 15 23 4 20 24 15 14 7 1 14 22
2024/20251.033 2 73 33 51 108 172 53 48 95 116 102 180
2025/20261.558 108 186 135 191 148 126 240 121 95 156 52 0
Totale 3.735